Tregzi (allogeneic reg T cell immunotherapy, HSPC and T cell-vldq)
Intravenous Plastic Bag, Injection (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: allogeneic reg T cell immunotherapy, HSPC and T cell-vldq
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Tregzi
Indications
The following indications are listed for Tregzi:
- Hematologic Malignancy
- Prevention Of Graft-Versus-Host Disease
Also known as: Graft Versus Host Disease Prophylaxis, Graft Versus Host Reaction Prophylaxis, Graft Vs. Host Disease Prophylaxis, Gvh Disease Prophylaxis, Gvhd Prophylaxis, Hematologic Cancer, Malignant Tumor Of Lymphoid, Hemopoietic, Or Related Tissue, Prevention Of Graft Versus Host Disease.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Stem Cell Immunotherapy/Corticosteroids
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Corticosteroids suppress the immune system. Concurrent use or premedication with a prophylactic corticosteroid may interfere with the activity of hematopoetic stem cell and T-cell immunotherapies.(1)
CLINICAL EFFECTS: Corticosteroids may decrease the efficacy of hematopoetic stem cell and T-cell immunotherapies.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer states use of corticosteroids as a premedication prior to infusion of hematopoetic stem cell and T-cell immunotherapy is strongly discouraged.(1)
DISCUSSION: Corticosteroids may decrease the efficacy of hematopoetic stem cell and T-cell immunotherapy.(1) The manufacturer states use of corticosteroids as a premedication prior to infusion of hematopoetic stem cell and T-cell immunotherapy is strongly discouraged.(1)
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Abnormal hepatic function tests
- Anemia
- Bacterial infection
- Chronic graft-versus-host disease
- Graft-versus-host disease
- Increased alanine transaminase
- Infection
- Leukopenia
- Lymphopenia
- Stomatitis
- Viral infection
Less Frequent
- Hematopoietic stem cell transplant failure
- Hepatic veno-occlusive disease
More Frequent
- Acute abdominal pain
- Diarrhea
- Edema
- Fever
- Fungal infection
- Hemorrhage
- Nausea
- Skin rash
- Vomiting
Less Frequent
- Pneumonia
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Hematologic malignancy | ||
| C96.9 | ICD10CM | Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified |
| Prevention of graft-versus-host disease | ||
| Z94.81 | ICD10CM | Bone marrow transplant status |
| Z94.84 | ICD10CM | Stem cells transplant status |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.